Form 4: Zimmer Biomet Director Syed A. Jafry Reports Acquisition of Phantom Stock Units and Restricted Stock Units

Director Syed A. Jafry reports acquisition of phantom stock units and restricted stock units in Zimmer Biomet Holdings, Inc.

Summary

• Syed A. Jafry, a director of Zimmer Biomet Holdings, Inc., filed a Form 4 on May 14, 2024, reporting transactions that occurred on May 10, 2024.
• The transactions involve the acquisition of phantom stock units and restricted stock units.
• Jafry acquired 616.726 phantom stock units at a price of $121.61.
• Jafry also acquired 1,068.991 restricted stock units.
• Following these transactions, Jafry beneficially owns 5,727.42 phantom stock units and 6,173.928 restricted stock units.
• The phantom stock units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
• The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a routine disclosure of stock unit acquisitions. It suggests confidence from the director but doesn't inherently indicate a major positive or negative outlook.

Positives

• The acquisition of stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The phantom stock units will be settled in shares of Zimmer Biomet common stock within 60 days of Jafry's departure as a director. The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Comparison to Industry Standards

• Stock ownership and equity-based compensation are common practices for directors in publicly traded companies like Zimmer Biomet.
• Companies such as Stryker, Johnson & Johnson, and Medtronic also utilize similar compensation structures to align the interests of their directors with those of the shareholders.
• The specific amounts and vesting schedules can vary based on company size, performance, and individual contributions.

Key Dates